Stock screenerAll disclosures → EDGAR →
RDY
Conviction 18HealthcareScan · Thu, Sep 24, 2026Dr Reddys Laboratories Ltd (RDY) closed at $12.29 (-0.81%) on Sep 24, 2026. Price is above its 50-day and below its 200-day moving average. RSI(14) 54, RS Rating 18, -20.1% from its 52-week high, -11.3% year to date. Sector: Healthcare · Drug Manufacturers - Specialty & Generic.
RDY$12.29-0.81%
ResistanceSupportVol 14Vol MA14 2.84M
Jun 26Jul 15Aug 3Aug 19Sep 8Sep 24
Price12.29
Change-0.81%
Gap-0.65%
Rel volume0.95×
Avg volume2.83M
Avg $ vol34.1M
SMA 2012.07
SMA 5012.11
SMA 20013.33
Price vs 50+1.50%
Price vs 200-7.83%
MA stackmixed
50/200 cross—
Supertrendup · 11.84
RSI (14)54
MACD hist0.08
MACD crossbull · 5d
Stoch %K / %D64 / 75
ADX (14)25
+DI / −DI34 / 29
RSI divergence—
MACD divergence—
ATR %1.96%
ADR %1.55%
52w high15.38
52w low11.38
From 52w high-20.09%
Above 52w low+8.00%
New 52w highNo
SqueezeOff
Bollinger width8.36%
%B0.72
Donchian pos64.46%
Donchian high12.72
Donchian low11.51
AVWAP (52w high)12.54
vs AVWAP high-2.00%
AVWAP (52w low)12.03
vs AVWAP low+2.15%
OBV trendFlat
Chaikin MF (20)-0.16
Today vs 20d0.95×
Avg vol (14d)2.84M
Avg vol (20d)2.83M
Avg $ vol (20d)34.1M
Market cap10.26B
RS Rating18 / 99
RS 3m (vs SPY)-23.90%
RS 6m (vs SPY)-28.21%
RS line new highNo
Trend template2/8
Technical rank44.8
1 week+0.82%
1 month-0.41%
3 months-19.41%
6 months-11.39%
1 year-15.30%
YTD-11.33%
P/E—
P/B—
P/S—
P/FCF—
EPS—
Div yield—
ROE—
ROA—
Debt/Eq—
Current—
EV/EBITDA—
Gross margin—
Net margin—
Rev growth—
EPS growth—
Price target—
Target upside—
Analyst rating—
Institutional15.71%
Ent. value10.26B
Revenue—
Net income—
Gross profit—
Free cash flow—
IndustryDrug Manufacturers - Specialty & Generic
ExchangeNYSE
Shares out834.65M
Employees27.53K
ListedWed, Apr 11, 2001
Free float3.59B
Float %100.0%
Short interest23.9M
Days to cover11.0d
Short volume33.3%
Squeeze score26 / 100
Next earnings—
EPS forecast—
Last EPS vs est$0.06 vs $0.17
Last surprise-64.7% miss
Setup gradeD
Conviction18 / 100
Pattern quality—
Tech rank44.8 / 100
Group rank59 / 100
Status laneNo active setup
Setup direction—
Pattern family
Resistance12.65
Support11.55
Days since event—
Candle confirm—
Recent news
- Nykredit A S Takes Position in Dr. Reddy's Laboratories Ltd $RDYMarketBeat · Wed, Sep 23, 2026
- Trading window closes at Dr. Reddy’s (NYSE: RDY) before Oct. 23 results meetingStock Titan · Tue, Sep 22, 2026
- DR REDDYS LABORATORIES LTD: 6-K filedSEC EDGAR · Tue, Sep 22, 2026
- In-person Nomura investor meet for Dr. Reddy’s (NYSE: RDY) on Sep 25Stock Titan · Mon, Sep 21, 2026
- Dr Reddy's Laboratories stock gains as Nomura meet nearsAD HOC NEWS · Mon, Sep 21, 2026
- Dr. Reddy’s Laboratories Ltd (RDY) Stock Analysis: A 9.6% Potential Upside in the Healthcare SectorDirectorsTalk Interviews · Mon, Sep 21, 2026
- Dr. Reddy's Laboratories stock holds steady as investors digest recent earnings and valuationAD HOC NEWS · Sun, Sep 20, 2026
Congress activity
Disclosed STOCK Act trades in RDY
No recent disclosed trades by Congress in RDY. STOCK Act filings can lag the trade by up to 45 days.
Insider activity
SEC Form 4 transactions in RDY
No recent insider (Form 4) filings in RDY. Insiders must file within two business days of a trade.
SEC filings
EDGAR filings in RDY · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.
Start free — 14-day full access →Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.